[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Arterial Thrombosis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 48 pages | ID: A566F38A5E50EN

US$ 1,599.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
2020 Arterial Thrombosis PIPELINE HIGHLIGHTS
Arterial Thrombosis is one of the widely researched conditions during 2020 with 8 companies actively focusing on realizing pipeline’s potential. Development of Arterial Thrombosis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Arterial Thrombosis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Arterial Thrombosis.

Good progress is anticipated during 2020 and 2021 with Arterial Thrombosis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Arterial Thrombosis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
The “Arterial Thrombosis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Arterial Thrombosis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Arterial Thrombosis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Arterial Thrombosis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Arterial Thrombosis DRUG PROFILES
Arterial Thrombosis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators
Arterial Thrombosis COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Arterial Thrombosis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Arterial Thrombosis. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 8 Arterial Thrombosis companies including company overview, key snapshot, contact information, and their strategies on accelerating Arterial Thrombosis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Astellas Pharma Inc, Bristol-Myers Squibb Company, GLSynthesis Inc, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, MDI Therapeutics Inc, Oasis Pharmaceuticals LLC, Thromboserin Ltd

  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Arterial Thrombosis
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners

1.1 Arterial Thrombosis- Disease overview
1.2 Arterial Thrombosis- Market Size
1.3 Arterial Thrombosis- Companies Involved


2.1 Arterial Thrombosis Pipeline by Phase
2.2 Arterial Thrombosis Pipeline by Mechanism of Action
2.3 Arterial Thrombosis Pipeline by Route of Administration
2.4 Arterial Thrombosis Pipeline- New Molecular Entities
2.5 Arterial Thrombosis Pipeline- Orphan Drug Designation/ Special Designation


3.1 Current Status
3.2 Arterial Thrombosis Drug Snapshot
3.3 Arterial Thrombosis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Astellas Pharma Inc Arterial Thrombosis Pipeline Insights and Clinical Trials
4.2 Bristol-Myers Squibb Company Arterial Thrombosis Pipeline Insights and Clinical Trials
4.3 GLSynthesis Inc Arterial Thrombosis Pipeline Insights and Clinical Trials
4.4 Jiangsu Hengrui Medicine Co Ltd Arterial Thrombosis Pipeline Insights and Clinical Trials
4.5 Johnson & Johnson Arterial Thrombosis Pipeline Insights and Clinical Trials
4.6 MDI Therapeutics Inc Arterial Thrombosis Pipeline Insights and Clinical Trials
4.7 Oasis Pharmaceuticals LLC Arterial Thrombosis Pipeline Insights and Clinical Trials
4.8 Thromboserin Ltd Arterial Thrombosis Pipeline Insights and Clinical Trials



6.1 Sources and Methodology
6.2 Contact Information

More Publications